Zoledronic Acid CAS 118072-93-8 Maʻemaʻe ≥99.7% API Factory Mea Kiʻekiʻe
Hoʻolako me ka maʻemaʻe kiʻekiʻe a me ka maikaʻi paʻa
Inoa Kemika: Zoledronic Acid
CAS: 118072-93-8
Manaʻo Farnesyl Diphosphate (FPP) Synthase Inhibitor
API Kūlana Kiʻekiʻe, Hana Hana Kūʻai
| Inoa Kimia | Zoledronic Acid |
| Nā huaʻōlelo like | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-Hydroxy-2-(1H-imidazol-1-yl)-ethylidene]ʻakika bisphosphonic |
| Helu CAS | 118072-93-8 |
| Helu CAT | RF-API90 |
| Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
| ʻĀpana Molekala | C5H10N2O7P2 |
| Kaumaha Molecular | 272.09 |
| Lae hehee | 193.0~204.0 ℃ |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| Ka nana aku | Keʻokeʻo a i ka pauka kristal keʻokeʻo |
| ʻIkepili | IR Spectrum o ka laana e pili ana i ka ma'amau kuhikuhi |
| pH | 2.0~4.0 |
| Ka hikiwawe | Hiki ke hoʻoheheʻe ʻia i loko o ka 0.1N Sodium Hydroxide Solution, hiki ke hoʻoheheʻe ʻia i ka wai a me ka 0.1N Hydrochloric Acid, hiki ʻole ke hoʻoheheʻe ʻia i ka Ethanol. |
| Na mea pili | |
| ʻO kēlā me kēia haumia kanaka | ≤0.10% |
| Huina paumaele | ≤0.30% |
| Nalo ma ka maloo | 5.0%~7.0% |
| Klorida | ≤0.02% |
| Phosphite | ≤0.50% |
| Phosphate | ≤0.50% |
| Nā Metala Kaumaha | ≤10ppm |
| Maemae | ≥99.7% |
| Kūlana hoʻāʻo | Kūlana ʻoihana |
| Hoʻohana | API, FPP Synthase Inhibitor, Hypercalcemia of Malignancy (HCM) |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
ʻO ka ʻakika Zoledronic (CAS 118072-93-8) he mea hoʻopaneʻe synthase ikaika bisphophonate farnesyl diphosphate (FPP) (IC50=20 nM).Kāohi i ka hoʻihoʻi ʻana o ka iwi osteoclast.Hoʻopaʻa pū i ka hōʻailona Ras a me ka ulu ʻana o ka maʻi tumora, a hoʻoulu i ka apoptosis i loko o nā pūnaewele maʻi pancreatic.Hoʻohuli i ka hoʻololi epithelial-mesenchymal a keʻakeʻa i ka hana hou ʻana o ka maʻi maʻi umauma ma o ka hana ʻole o NF-κB.Ua ʻae ʻia ʻo Zoledronic acid e ka US FDA i ka makahiki 2001 no ka mālama ʻana i ka hypercalcemia o ka malignancy, kahi pilikia metabolic e hiki ke hoʻoweliweli i ke ola.Hiki ke loaʻa ka Hypercalcemia o ka maʻi maʻi i loko o 50% o nā maʻi i loaʻa i ka maʻi maʻi maʻi umauma kiʻekiʻe, ka myeloma lehulehu, a me ka maʻi maʻi ʻaʻai māmā liʻiliʻi.Ke kū nei kēia ʻano i ka wā i hoʻoulu ʻia ai nā mea kemika i hana ʻia e ka maʻi maʻi maʻi.Ke piʻi aʻe ka hoʻohaʻahaʻa iwi, aia ka hoʻokuʻu ʻana o ka calcium i loko o ka plasma.Ke piʻi koke ka nui o ka calcium i ka serum, ʻaʻole hiki i nā puʻupaʻa ke hoʻopaʻa i ka nui, a me ka hopena hypercalcemia.Hoʻemi maikaʻi ʻo Zoledronic acid i ka nui o ka calcium plasma ma o ke kāohi ʻana i ka hoʻihoʻi ʻana o ka iwi (ka hoʻopaʻa ʻana i ka hana osteoclastic a me ka hoʻokomo ʻana i ka apoptosis osteoclast).Eia kekahi, ua ʻae ʻia ka waikawa zoledronic e ka US FDA no ka mālama ʻana i nā myeloma lehulehu a me nā metastases iwi e pili ana i nā maʻi maʻi maʻi maʻi maʻi maʻi maʻi (e laʻa, hoʻomoe a me ka māmā).
